IL-17A   Click here for help

GtoPdb Ligand ID: 4982

Synonyms: CTLA-8 | interleukin-17 alpha
Immunopharmacology Ligand
Comment: Forms homodimeric ligand IL-17A, or heterodimeric IL-17A/IL-17F.
Species: Human
Natural/Endogenous Targets
Target
Interleukin-17 receptor
Selectivity at catalytic receptors
Key to terms and symbols Click column headers to sort
Target Sp. Type Action Value Parameter Concentration range (M) Reference
Interleukin-17 receptor Ligand is endogenous in the given species Hs Agonist Agonist - - -
Selectivity at ligand targets
Key to terms and symbols Click column headers to sort
Target Sp. Type Action Value Parameter Concentration range (M) Reference
COVA322 Hs None Binding 10.4 pKd - 15
pKd 10.4 (Kd 3.6x10-11 M) [15]
Description: Binding affinity determined using BIAcore technology.
Other ligands which bind to or alter the activity of this ligand
Key to terms and symbols Click column headers to sort
Ligand Sp. Type Action Value Parameter Concentration range (M) Reference
sonelokimab Peptide Primary target of this compound Hs Antibody Binding 12.4 pKd - 4
pKd 12.4 (Kd 4x10-13 M) [4]
vunakizumab Peptide Primary target of this compound Hs Antibody Binding >12.0 pKd - 16
pKd >12.0 (Kd <1x10-12 M) [16]
Description: Measured using Biacore technology
ixekizumab Peptide Approved drug Primary target of this compound Hs Antibody Binding >11.7 pKd - 2
pKd >11.7 (Kd <2x10-12 M) [2]
Description: Binding affinity of mAbs 104, 121 and 126 from patent US7838638
tibulizumab Peptide Primary target of this compound Hs Antibody Binding 10.9 pKd - 3
pKd 10.9 (Kd 1.4x10-11 M) [3]
bimekizumab Peptide Primary target of this compound Hs Antibody Binding 10.7 pKd - 1
pKd 10.7 (Kd 2.1x10-11 M) [1]
Description: Biacore assay using recombinant human IL-17A
secukinumab Peptide Approved drug Primary target of this compound Hs Antibody Binding 9.9 pKd - 7
pKd 9.9 (Kd 1.22x10-10 M) [7]
Description: Binding affinity for recombinant human IL-17
secukinumab Peptide Approved drug Primary target of this compound Hs Antibody Binding 8.7 pIC50 - 7
pIC50 8.7 (IC50 2.1x10-9 M) [7]
Description: Inhibition of IL-17-induced IL-6 production by human dermal fibroblasts.
remtolumab Peptide Primary target of this compound Hs Antibody Binding - - -